Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Gains from Sales and Divestitures (2016)

Historic Gains from Sales and Divestitures for NovaBay Pharmaceuticals (NBY) over the last 8 years, with Q3 2016 value amounting to $74.0.

  • NovaBay Pharmaceuticals' Gains from Sales and Divestitures fell 9995.0% to $74.0 in Q3 2016 from the same period last year, while for Sep 2016 it was $74.0, marking a year-over-year decrease of 9995.0%. This contributed to the annual value of $6000.0 for FY2015, which is 5000.0% up from last year.
  • Per NovaBay Pharmaceuticals' latest filing, its Gains from Sales and Divestitures stood at $74.0 for Q3 2016, which was down 9995.0% from $74.0 recorded in Q2 2016.
  • In the past 5 years, NovaBay Pharmaceuticals' Gains from Sales and Divestitures ranged from a high of $4.9 million in Q3 2013 and a low of -$56000.0 during Q1 2014
  • Over the past 5 years, NovaBay Pharmaceuticals' median Gains from Sales and Divestitures value was $64000.0 (recorded in 2014), while the average stood at $1.3 million.
  • In the last 5 years, NovaBay Pharmaceuticals' Gains from Sales and Divestitures tumbled by 10118.47% in 2014 and then soared by 26250.0% in 2015.
  • Quarter analysis of 5 years shows NovaBay Pharmaceuticals' Gains from Sales and Divestitures stood at $28000.0 in 2012, then plummeted by 64.29% to $10000.0 in 2013, then tumbled by 60.0% to $4000.0 in 2014, then skyrocketed by 50.0% to $6000.0 in 2015, then crashed by 98.77% to $74.0 in 2016.
  • Its Gains from Sales and Divestitures was $74.0 in Q3 2016, compared to $74.0 in Q2 2016 and $72000.0 in Q1 2016.